Log In
Friday 21st October 2016

Osteoporosis guidance re-evaluated by NICE

30th March 2009

The National Institute for Health and Clinical Excellence has said it will be releasing "its economic model to consultees" as part of its re-evaluation of its osteoporosis guidance.

NICE had been taken to the High Court by Servier Laboratories because of its guidance on the use of the drug Protelos. It is estimated that up to 15% of women with the condition - who cannot take biosphosphates - could be in danger of fractures. The current guidance will remain in place until the re-evaluation is finished.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Article Information

Title: Osteoporosis guidance re-evaluated by NICE
Author: Jess Laurence
Article Id: 10776
Date Added: 30th Mar 2009


GP Online

Recent Related Articles

Guidance to protect lone working nurses

Primary care funding could be reduced

NICE approves new cancer drugs


Add to scrapbook
Show Comments
Add comment
Find all related articles


Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2016